Has the use of disease-modifying anti-rheumatic drugs changed as a consequence of controlled access to high-cost biological agents through the Pharmaceutical Benefits Scheme?

Internal Medicine Journal

Volumn 37, Issue 9, 2007, Pages 601-606

  Lu, C Y ^a   Williams, K M ^a   Day, R O ^a  

^a ST VINCENT S HOSPITAL   (Australia)

Author keywords

Access; Biologicals; High cost medicine; Pharmaceutical Benefits Scheme; Rheumatoid arthritis

Indexed keywords

AURANOFIN; AUROTHIOMALATE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GOLD COMPLEX; HYDROXYCHLOROQUINE; LEFLUNOMIDE; METHOTREXATE; PENICILLAMINE; SALAZOSULFAPYRIDINE;

ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG COST; DRUG INDUSTRY; DRUG USE; DRUG UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; PRESCRIPTION; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS;

ANTIRHEUMATIC AGENTS; AUSTRALIA; BIOLOGICAL PRODUCTS; COSTS AND COST ANALYSIS; HUMANS; INSURANCE BENEFITS; PRESCRIPTIONS, DRUG; RETROSPECTIVE STUDIES; RHEUMATIC DISEASES;

EID: 34547864986     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2007.01396.x     Document Type: Article

References (24)

1. Wong JB, Ramey DR, Singh G. Long-term morbidity, mortality, and economics of rheumatoid arthritis. Arthritis Rheum 2001 44 : 2746 9.
2. Stenger AA, van Leeuwen MA, Houtman PM, Bryuyn GA, Speerstra F, Barendsen BC et al. Early effective suppression of inflammation in rheumatoid arthritis reduces radiographic progression. Br J Rheumatol 1998 37 : 1157 63.
3. Egsmose C, Lund B, Borg G, Pettersson H, Berg E, Brodin U et al. Patients with rheumatoid arthritis benefit from early 2nd line therapy: 5 year follow-up of a prospective double blind placebo controlled study. J Rheumatol 1995 12 : 2208 13.
4. van der Heide A, Jacobs JW, Bijlsma JW, Heurkens AH, van Booma-Frankfort C, van der Veen MJ et al. The effectiveness of early treatment with 'second-line' antirheumatic drugs. A randomized, controlled trial. Ann Intern Med 1996 124 : 699 707.
5. Mottonen T, Hannonen P, Korpela M, Nissila M, Kautiainen H, Ilonen J et al. Delay to institution of therapy and induction of remission using single-drug or combination-disease-modifying antirheumatic drug therapy in early rheumatoid arthritis. Arthritis Rheum 2002 46 : 894 8.
6. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum 2002 46 : 328 46.
7. Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000 343 : 1586 93.
8. Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA et al. Adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate. Arthritis Rheum 2003 48 : 35 45.
9. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000 343 : 1594 602.
10. Commonwealth Department of Health and Ageing. Schedule of Pharmaceutical Benefits for Approved Pharmacists and Medical Practitioners Canberra, 2005.
11. Lu CY, Williams KM, Day RO, March LM, Sansom L, Bertouch J. Access to high cost drugs in Australia: risk sharing scheme may set a new paradigm. BMJ 2004 329 : 415 16.
12. Breen CL, Degenhardt LJ, Bruno RB, Roxburgh AD, Jenkinson R. The effects of restricting publicly subsidized temazepam capsules on benzodiazepine use among injecting drug users in Australia. Med J Aust 2004 181 : 300 4.
13. Handelsman DJ. Trends and regional differences in testosterone prescribing in Australia, 1991-2001. Med J Aust 2004 181 : 419 22.
14. Bykerk VP, Keystone EC. What are the goals and principles of management in the early treatment of rheumatoid arthritis? Best Pract Res Clin Rheumatol 2005 19 : 147 61.
15. Commonwealth Department of Health and Ageing. Australian Statistics on Medicines 2001-2002. Canberra, 2002.
16. Gibson PR, Iser J. Inflammatory bowel disease. Aust Fam Physician 2005 34 : 233 7.
17. Australian Bureau of Statistics. Australian Historical Population Statistics. Canberra : ABS 2006. Cat. No.: 3105.0.65.001.
18. Australian Institute of Health and Welfare. Arthritis and musculoskeletal conditions in Australia, 2005. Canberra : AIHW 2005. AIHW Cat. No.: PHE67.
19. Eberhardt K, Rydgren L, Fex E, Svensson B, Wollheim FA. D-penicillamine in early rheumatoid arthritis: experience from a 2-year double blind placebo controlled study. Clin Exp Rheumatol 1996 14 : 625 31.
20. Chan V, Tett SE. Changes in use of disease-modifying anti-rheumatic drugs in Australia over the period 1992-2004. Pharmacoepidemiol Drug Saf 2006 15 : 462 8.
21. Lu CY, Williams KM, Day RO. Accessing health outcome data on high cost medicines in Australia. Med J Aust 2006 184 : 411 13.
22. Australian Government The Office of the Privacy Commissioner. Review of the Medicare and PBS Privacy Guidelines issued under section 135AA of the National Health Act 1953: Issues Paper. Canberra, 2004.
23. Edwards CJ, Arden NK, Fisher D, Saperia JC, Reading I, Van Staa TP et al. The changing use of disease-modifying anti-rheumatic drugs in individuals with rheumatoid arthritis from the United Kingdom General Practice Research Database. Rheumatology 2005 44 : 1394 8.
24. Carli C, Ehlin AGC, Klareskog L, Lindblad S, Montgomery SM. Trends in DMARD prescription in early rheumatoid arthritis are influenced more by hospital setting than patient or disease characteristics. Ann Rheum Dis 2006 65 : 1102 5.